# Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

> **NCT06028074** · PHASE1,PHASE2 · RECRUITING · sponsor: **Georgiamune Inc** · enrollment: 111 (estimated)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** GIM122

## Key facts

- **NCT ID:** NCT06028074
- **Lead sponsor:** Georgiamune Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06028074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06028074, "Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06028074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*